HC Wainwright upgraded Kyverna Therapeutics Inc. KYTX, citing three upcoming data sets through mid-2025. In its first quarter 2025 earnings released, the company highlighted: Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS). The trial is on track for topline data and a biologics license application (BLA) filing is
Geely Automobile Holdings GELYF announced that the company will share its battery safety patents at the Shanghai Auto Show. What Happened: The Chinese automaker revealed on Wednesday the “Geely Global Safety Center,” which the company says is the world’s largest standalone safety lab. It also unveiled a new battery brand dubbed the “Geely Golden Short
The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.’s ALDX resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for dry eye disease. The FDA stated that the NDA “failed to demonstrate efficacy in adequate and well-controlled studies in treating ocular symptoms associated